Related Experiment Videos
Mirtazepine: heir apparent to amitriptyline?
M P Davis1, E D Dickerson, M Pappagallo
1Harry R. Horvitz Center for Palliative Medicine, Cleveland Clinic Taussig Cancer Center, Cleveland, Ohio, USA.
The American Journal of Hospice & Palliative Care
|June 16, 2001
Summary
Mirtazepine, an atypical antidepressant, offers significant benefits for palliative care patients. Its unique pharmacological profile makes it a promising therapeutic option, though cost is a consideration.
Area of Science:
- Pharmacology
- Geriatric Medicine
- Palliative Care
Background:
- Hospice and palliative care require effective therapeutic options.
- Antidepressants play a role in managing symptoms in long-term care settings.
- Mirtazepine's unique pharmacological profile warrants investigation for these patient populations.
Purpose of the Study:
- To evaluate mirtazepine as a potential therapeutic agent in hospice, palliative, and long-term care.
- To examine the benefits and drawbacks of mirtazepine in these settings.
Main Methods:
- Review of mirtazepine's pharmacological properties.
- Evaluation of existing literature on mirtazepine's efficacy and safety.
- Assessment of its suitability for palliative and long-term care.
Main Results:
- Mirtazepine is an atypical antidepressant with noradrenergic and specific serotonergic antagonism (NaSSa).
- It presents multiple additional benefits beyond depression management.
- Its unique profile suggests potential as a "designer drug" for palliative medicine.
Conclusions:
- Mirtazepine demonstrates significant potential as a beneficial drug in palliative and long-term care.
- Its unique pharmacological actions may offer advantages over traditional antidepressants.
- Cost may be a limiting factor in its widespread adoption.